Search

Your search keyword '"Robert J. Pignolo"' showing total 76 results

Search Constraints

Start Over You searched for: Author "Robert J. Pignolo" Remove constraint Author: "Robert J. Pignolo" Search Limiters Peer Reviewed Remove constraint Search Limiters: Peer Reviewed
76 results on '"Robert J. Pignolo"'

Search Results

1. Study methodology and insights from the palovarotene clinical development program in fibrodysplasia ossificans progressiva

2. Cell Senescence in Heterotopic Ossification

Catalog

Books, media, physical & digital resources

3. Application of Innovative Subject Recruitment System for Batch Enrollment: A Pilot Study

4. An unbiased proteomics approach to identify the senescence-associated secretory phenotype of human bone marrow-derived mesenchymal stem cells

5. A new gene set identifies senescent cells and predicts senescence-associated pathways across tissues

6. The HIF-1α and mTOR Pathways Amplify Heterotopic Ossification

7. Current challenges and opportunities in the care of patients with fibrodysplasia ossificans progressiva (FOP): an international, multi-stakeholder perspective

8. Local senolysis in aged mice only partially replicates the benefits of systemic senolysis

9. Accelerated Aging in Cyclophilin B–Deficient Mice Downstream of p21‐Cip1/Waf1

10. Prevalence of fibrodysplasia ossificans progressiva (FOP) in the United States: estimate from three treatment centers and a patient organization

11. Rural–urban health disparities for mood disorders and obesity in a midwestern community

12. Patients with ACVR1R206H mutations have an increased prevalence of cardiac conduction abnormalities on electrocardiogram in a natural history study of Fibrodysplasia Ossificans Progressiva

13. Paths of Emergency Department Care: Development of a Decision Aid to Facilitate Shared Decision Making in Goals of Care Discussions in the Acute Setting

14. Fibrodysplasia Ossificans Progressiva: What Have We Achieved and Where Are We Now? Follow-up to the 2015 Lorentz Workshop

15. Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney diseaseResearch in context

16. Natural history of fibrodysplasia ossificans progressiva: cross-sectional analysis of annotated baseline phenotypes

19. Retinoid Agonists in the Targeting of Heterotopic Ossification

20. International physician survey on management of FOP: a modified Delphi study

21. Corrigendum to ‘Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease’ EBioMedicine 47 (2019) 446–456

22. Fibrodysplasia Ossificans Progressiva (FOP): A Segmental Progeroid Syndrome

23. Correction to: Natural history of fibrodysplasia ossificans progressiva: cross-sectional analysis of annotated baseline phenotypes

24. Mouse models of telomere dysfunction phenocopy skeletal changes found in human age-related osteoporosis

25. Functional Testing of Bone Morphogenetic Protein (BMP) Pathway Variants Identified on Whole‐Exome Sequencing in a Patient with Delayed‐Onset Fibrodysplasia Ossificans Progressiva (<scp>FOP</scp>) UsingACVR1R206H‐Specific Human Cellular and Zebrafish Models

26. Gene Therapy for Fibrodysplasia Ossificans Progressiva

28. Palovarotene for Fibrodysplasia Ossificans Progressiva (FOP): Results of a Randomized, Placebo-Controlled, Double-Blind Phase 2 Trial

29. Druggable targets, clinical trial design and proposed pharmacological management in fibrodysplasia ossificans progressiva

30. Targeted Reduction of Senescent Cell Burden Alleviates Focal Radiotherapy‐Related Bone Loss

31. Targeted clearance of p21 ‐ but not p16 ‐positive senescent cells prevents radiation‐induced osteoporosis and increased marrow adiposity

32. The Fibrodysplasia Ossificans Progressiva Physical Function Questionnaire (FOP-PFQ): A patient-reported, disease-specific measure

33. Bone Marrow Adiposity in Models of Radiation- and Aging-Related Bone Loss Is Dependent on Cellular Senescence

34. Incidence of Respiratory Syncytial Virus Infection in Older Adults Before and During the COVID-19 Pandemic

35. Recommendations for Diagnosis and Treatment of Pseudohypoparathyroidism and Related Disorders: An Updated Practical Tool for Physicians and Patients

36. Creating the Next Generation of Translational Geroscientists

37. Targeting Cell Senescence for the Treatment of Age-Related Bone Loss

38. Clinical staging of Fibrodysplasia Ossificans Progressiva (FOP)

39. Circulating osteogentic precursor cells in non-hereditary heterotopic ossification

40. Prevalence and risk factors for kidney stones in fibrodysplasia ossificans progressiva

41. Acute unilateral hip pain in fibrodysplasia ossificans progressiva (FOP)

42. Imaging assessment of fibrodysplasia ossificans progressiva: Qualitative, quantitative and questionable

43. Targeting cellular senescence prevents age-related bone loss in mice

44. A cumulative analogue joint involvement scale (CAJIS) for fibrodysplasia ossificans progressiva (FOP)

45. The congenital great toe malformation of fibrodysplasia ossificans progressiva? - A close call

46. Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research

47. Teriparatide as a Systemic Treatment for Lower Extremity Nonunion Fractures: A Case Series

48. Brief Report: Long-Term Functional Engraftment of Mesenchymal Progenitor Cells in a Mouse Model of Accelerated Aging

49. Impairment of osteoblast differentiation due to proliferation-independent telomere dysfunction in mouse models of accelerated aging

50. Fibrodysplasia ossificans progressiva: a blueprint for metamorphosis